Ignite Creation Date:
2024-07-17 @ 11:05 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06499571
Status:
COMPLETED
Last Update Posted:
2024-07-12
First Post:
2024-04-23
Brief Title:
Geographic Atrophy Long-Terms Outcomes Study
Sponsor:
Apellis Pharmaceuticals Inc
Organization:
Apellis Pharmaceuticals Inc
Study Overview
Official Title:
GALTOS Geographic Atrophy Long-Terms Outcomes Study An Ambispective Noninterventional Study to Describe the Patient Demographics and Outcomes of Patients With Geographic Atrophy GA Secondary to AMD in Clinical Practice
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GALTOS
Brief Summary:
The purpose of this study is to describe functional and long-term clinical outcomes of patients with a diagnosis of Geographic Athrophy secondary to Age related Macular Degenaration in Clinical Practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None